We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+9.64%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$916M
AUM Growth
+$22.5M
Cap. Flow
+$9.33M
Cap. Flow %
1.02%
Top 10 Hldgs %
50.42%
Holding
61
New
8
Increased
22
Reduced
19
Closed
5

Top Buys

Rank Stock Value
1
CALA
Calithera Biosciences, Inc
CALA
+$21.2M
2
IDYA icon
IDEAYA Biosciences
IDYA
+$16.4M
3
CYTK icon
Cytokinetics
CYTK
+$13.3M
4
AKRO
Akero Therapeutics
AKRO
+$12.3M
5
ACIU icon
AC Immune
ACIU
+$12M

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$62.5M
2
ARQL
Arqule Inc
ARQL
+$38.5M
3
BPMC
Blueprint Medicines
BPMC
+$10.5M
4
ARGX icon
argenx
ARGX
+$10.1M
5
VBIV
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
+$8.83M

Sector Composition

Rank Sector Weight
1 Healthcare 90.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANAB icon
26
AnaptysBio
ANAB
$1.63B
$11.6M 1.26%
205,265
-15,000
-7% -$1.08M
SPRO icon
27
Spero Therapeutics
SPRO
$69.5M
$10.8M 1.18%
939,704
+478,998
+104% +$5.77M
CRVS icon
28
Corvus Pharmaceuticals
CRVS
$1.11B
$10.4M 1.13%
2,774,750
+665,408
+32% +$2.61M
MRSN
29
DELISTED
Mersana Therapeutics
MRSN
$10.1M 1.1%
99,916
-84
-0.1% -$9.89K
VSTM icon
30
Verastem
VSTM
$536M
$9.56M 1.04%
527,416
+234,583
+80% +$5.31M
BLRX
31
BioLineRX
BLRX
$11.7M
$9.49M 1.04%
43,326
– –
FWP
32
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$8.73M 0.95%
1,211,440
– –
XFOR icon
33
X4 Pharmaceuticals
XFOR
$377M
$8.71M 0.95%
+19,350
New +$9.84M
PRVL
34
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$8.67M 0.95%
+656,483
New +$9.57M
ARQL
35
DELISTED
Arqule Inc
ARQL
$8.52M 0.93%
773,459
-5,535,287
-88% -$38.5M
GNCA
36
DELISTED
Genocea Biosciences, Inc.
GNCA
$8.23M 0.9%
2,100,305
+1,121,775
+115% +$5.85M
EIGR
37
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$7.16M 0.78%
22,500
– –
OVID icon
38
Ovid Therapeutics
OVID
$442M
$6.63M 0.72%
3,583,236
+290,236
+9% +$518K
CTIC
39
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$5.96M 0.65%
6,929,690
– –
LITS
40
Lite Strategy Inc
LITS
$33.6M
$5.55M 0.61%
111,064
-23,874
-18% -$1.4M
GMDA
41
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$5.08M 0.55%
+1,000,000
New +$7.85M
VIRX
42
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$4.92M 0.54%
193,441
+128,074
+196% +$4.95M
ALPN
43
DELISTED
Alpine Immune Sciences Inc
ALPN
$4.85M 0.53%
1,151,717
-50,000
-4% -$289K
FSTX
44
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$4.8M 0.52%
325,425
+87,500
+37% +$2.34M
PHXM
45
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
$4.48M 0.49%
62,500
– –
CDTX
46
DELISTED
Cidara Therapeutics
CDTX
$4.46M 0.49%
132,645
+47,111
+55% +$1.96M
EPIX
47
DELISTED
ESSA Pharma
EPIX
$3.08M 0.34%
1,329,700
+749,332
+129% +$1.85M
SURF
48
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$2.88M 0.31%
1,021,234
+569,384
+126% +$2.27M
RLM
49
DELISTED
Realm Therapeutics plc American Depositary Shares
RLM
$2.57M 0.28%
909,759
+296,870
+48% +$980K
RGLS
50
DELISTED
Regulus Therapeutics
RGLS
$2.54M 0.28%
203,570
+98,376
+94% +$1.13M
1
2
3

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q2 2019 Portfolio in Review

As of Q2 2019, BVF Inc held 61 positions worth $916M, up 2.5% from $893M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

BVF Inc's Q2 2019 filing shows 8 new, 22 increased, 19 reduced and 5 closed positions. Its largest new stake was IDEAYA Biosciences: 1,505,429 shares worth $15M. The largest sale was Array Biopharma Inc, an estimated $62.5M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 90% a quarter earlier.

  • BVF Inc's largest Q2 2019 buy was IDEAYA Biosciences: 1,505,429 shares worth $15M.
  • BVF Inc added most to Calithera Biosciences, Inc in Q2 2019, an estimated $21.2M increase.
  • BVF Inc's biggest Q2 2019 reduction was Array Biopharma Inc, cutting an estimated $62.5M.
  • BVF Inc fully exited argenx in Q2 2019, selling an estimated $10.1M.
  • BVF Inc's ten largest holdings make up 50% of its $916M portfolio in Q2 2019.
  • BVF Inc opened 8 new positions and closed 5 in Q2 2019.
  • BVF Inc's portfolio value rose 2.5% quarter-over-quarter to $916M.

Based on BVF Inc's 13F filing for Q2 2019, filed 14 Aug 2019.